Krystal Biotech
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 275
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 97
0.78% more ownership
Funds ownership: 94.91% [Q1] → 95.68% (+0.78%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
9% less funds holding
Funds holding: 298 [Q1] → 272 (-26) [Q2]
11% less call options, than puts
Call options by funds: $60.6M | Put options by funds: $68M
23% less capital invested
Capital invested by funds: $4.93B [Q1] → $3.8B (-$1.13B) [Q2]
35% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 63
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
|
HC Wainwright & Co.
Joseph Pantginis
|
$240
|
Buy
Reiterated
|
15 Sep 2025 |
|
Chardan Capital
Geulah Livshits
|
$216
|
Buy
Maintained
|
22 Aug 2025 |
|
Citigroup
Yigal Nochomovitz
|
$166
|
Neutral
Maintained
|
5 Aug 2025 |
|
B of A Securities
Alec Stranahan
|
$192
|
Buy
Maintained
|
22 Jul 2025 |
|
Citigroup
Carly Kenselaar
|
$176
|
Neutral
Maintained
|
10 Jul 2025 |
|
Clear Street
Bill Maughan
|
$190
|
Buy
Initiated
|
1 Jul 2025 |
Financial journalist opinion
Based on 5 articles about KRYS published over the past 30 days
